More cuts at troubled Point Therapeutics

The troubles at Point Therapeutics continue as the company announced today that it made major cuts to its management team. On the chopping block were Donald Kiepert, Chairman and CEO; Richard Small, Senior Vice President and CFO; Michael Duffy, Senior Vice President and General Counsel; and Barry Jones, PhD., Senior Vice President and CSO. In May the Boston-based company announced that it would cut its work force by 60 percent after the FDA put a hold on Point's failed lead drug development program.

- see Point's release on the cuts

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.